Evolent Health Stock Price To Earnings To Growth
EVH Stock | USD 9.51 0.26 2.66% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Evolent Health's long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Evolent Health Company Price To Earnings To Growth Analysis
Evolent Health's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Evolent Health Price To Earnings To Growth | (1.37) X |
Most of Evolent Health's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evolent Health is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Competition |
Based on the latest financial disclosure, Evolent Health has a Price To Earnings To Growth of -1.37 times. This is 292.96% lower than that of the Health Care Technology sector and significantly lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 128.02% higher than that of the company.
Evolent Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evolent Health's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evolent Health could also be used in its relative valuation, which is a method of valuing Evolent Health by comparing valuation metrics of similar companies.Evolent Health is currently under evaluation in price to earnings to growth category among its peers.
Evolent Fundamentals
Return On Equity | -0.0924 | ||||
Return On Asset | -4.0E-4 | ||||
Profit Margin | (0.05) % | ||||
Operating Margin | 0 % | ||||
Current Valuation | 1.8 B | ||||
Shares Outstanding | 117.4 M | ||||
Shares Owned By Insiders | 1.54 % | ||||
Shares Owned By Institutions | 98.46 % | ||||
Number Of Shares Shorted | 17.55 M | ||||
Price To Earning | (13.88) X | ||||
Price To Book | 1.25 X | ||||
Price To Sales | 0.49 X | ||||
Revenue | 2.55 B | ||||
Gross Profit | 365.72 M | ||||
EBITDA | 84.85 M | ||||
Net Income | (61.62 M) | ||||
Cash And Equivalents | 104.2 M | ||||
Cash Per Share | 1.57 X | ||||
Total Debt | 713.67 M | ||||
Debt To Equity | 0.56 % | ||||
Current Ratio | 1.03 X | ||||
Book Value Per Share | 8.07 X | ||||
Cash Flow From Operations | 18.77 M | ||||
Short Ratio | 5.17 X | ||||
Earnings Per Share | (1.22) X | ||||
Price To Earnings To Growth | (1.37) X | ||||
Target Price | 15.31 | ||||
Number Of Employees | 4.5 K | ||||
Beta | 0.82 | ||||
Market Capitalization | 1.17 B | ||||
Total Asset | 2.54 B | ||||
Retained Earnings | (780.82 M) | ||||
Working Capital | (108.38 M) | ||||
Current Asset | 184.46 M | ||||
Current Liabilities | 59.51 M | ||||
Net Asset | 2.54 B |
About Evolent Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evolent Health's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evolent Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evolent Health based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Evolent Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evolent Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evolent Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evolent Health Stock:Check out Evolent Health Piotroski F Score and Evolent Health Altman Z Score analysis. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Business Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolent Health. If investors know Evolent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Evolent Health is measured differently than its book value, which is the value of Evolent that is recorded on the company's balance sheet. Investors also form their own opinion of Evolent Health's value that differs from its market value or its book value, called intrinsic value, which is Evolent Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolent Health's market value can be influenced by many factors that don't directly affect Evolent Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolent Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolent Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolent Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.